MolPharm

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


Molecular Pharmacology Fast Forward
First published on June 18, 2007; DOI: 10.1124/mol.107.037093


0026-895X/07/7203-761-768$20.00
Mol Pharmacol 72:761-768, 2007

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
mol.107.037093v1
72/3/761    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kaivosaari, S.
Right arrow Articles by Finel, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kaivosaari, S.
Right arrow Articles by Finel, M.

Nicotine Glucuronidation and the Human UDP-Glucuronosyltransferase UGT2B10

Sanna Kaivosaari, Päivi Toivonen, Leah M. Hesse, Mikko Koskinen, Michael H. Court, and Moshe Finel

Department of Pharmacokinetics and Bioanalytics, Orion Corporation Orion Pharma, Espoo, Finland (S.K., P.T., M.K.); Division of Pharmaceutical Chemistry, Faculty of Pharmacy, University of Helsinki, Helsinki, Finland (S.K., P.T.); Molecular Pharmacogenetics Laboratory, Department of Pharmacology and Experimental Therapeutics, Tufts University School of Medicine, Boston, MA (L.M.H., M.H.C.); and Drug Discovery and Development Technology Center, Faculty of Pharmacy, University of Helsinki, Helsinki, Finland (M.F.)

Nicotine biotransformation affects the smoking habits of addicted individuals and therefore their health risk. Using an improved analytical method, we have discovered that the human UDP-glucuronosyltransferase (UGT) 2B10, a liver enzyme previously unknown to conjugate nicotine or exhibit considerable activity toward any compound, plays a major role in nicotine inactivation by direct conjugation with glucuronic acid at the aromatic nitrogen atom. The Km value of recombinant UGT2B10 for nicotine (0.29 mM) was similar to that determined for human liver microsomes (0.33 mM), whereas the Km value of UGT1A4 for nicotine was almost 10-fold greater (2.4 mM). UGT2B10 was also more active than UGT1A4 in N-glucuronidation of cotinine (oxidative nicotine metabolite), whereas UGT2B7 exhibited only low nicotine glucuronidation activity and was essentially inactive toward cotinine. UGT1A9 did not glucuronidate nicotine or cotinine. Quantitative reverse transcription-polymerase chain reaction showed that UGT2B10 mRNA was exclusively expressed in human liver, whereas UGTs 1A4 and 2B7 were expressed at comparable, although somewhat lower, levels in liver and several other extrahepatic tissues, including kidney and intestine. These findings for UGT2B10 (but not for UGT1A4 and UGT2B7) were mirrored by human tissue activities because nicotine and cotinine glucuronidation rates in intestine microsomes were less than 0.1% that of human liver microsomes. These novel findings solve two seemingly separate questions: which UGT is primarily responsible for nicotine glucuronidation in human liver, and what conjugation reactions are catalyzed by UGT2B10.


Received for publication April 13, 2007.

Accepted for publication June 18, 2007.

Address correspondence to: Dr. Moshe Finel, DDTC, Faculty of Pharmacy, University of Helsinki, P.O. Box 56 (Viikinkaari 5), 00014 Helsinki, Finland. E-mail: moshe.finel{at}helsinki.fi




This article has been cited by other articles:


Home page
Drug Metab. Dispos.Home page
O. Kerdpin, P. I. Mackenzie, K. Bowalgaha, M. Finel, and J. O. Miners
Influence of N-Terminal Domain Histidine and Proline Residues on the Substrate Selectivities of Human UDP-Glucuronosyltransferase 1A1, 1A6, 1A9, 2B7, and 2B10
Drug Metab. Dispos., September 1, 2009; 37(9): 1948 - 1955.
[Abstract] [Full Text] [PDF]


Home page
Antimicrob. Agents Chemother.Home page
J. Tarning, R. McGready, N. Lindegardh, E. A. Ashley, M. Pimanpanarak, B. Kamanikom, A. Annerberg, N. P. J. Day, K. Stepniewska, P. Singhasivanon, et al.
Population Pharmacokinetics of Lumefantrine in Pregnant Women Treated with Artemether-Lumefantrine for Uncomplicated Plasmodium falciparum Malaria
Antimicrob. Agents Chemother., September 1, 2009; 53(9): 3837 - 3846.
[Abstract] [Full Text] [PDF]


Home page
Drug Metab. Dispos.Home page
T. Izukawa, M. Nakajima, R. Fujiwara, H. Yamanaka, T. Fukami, M. Takamiya, Y. Aoki, S.-i. Ikushiro, T. Sakaki, and T. Yokoi
Quantitative Analysis of UDP-Glucuronosyltransferase (UGT) 1A and UGT2B Expression Levels in Human Livers
Drug Metab. Dispos., August 1, 2009; 37(8): 1759 - 1768.
[Abstract] [Full Text] [PDF]


Home page
Drug Metab. Dispos.Home page
K. Itaaho, M. H. Court, P. Uutela, R. Kostiainen, A. Radominska-Pandya, and M. Finel
Dopamine Is a Low-Affinity and High-Specificity Substrate for the Human UDP-Glucuronosyltransferase 1A10
Drug Metab. Dispos., April 1, 2009; 37(4): 768 - 775.
[Abstract] [Full Text] [PDF]


Home page
Drug Metab. Dispos.Home page
S. Ohno and S. Nakajin
Determination of mRNA Expression of Human UDP-Glucuronosyltransferases and Application for Localization in Various Human Tissues by Real-Time Reverse Transcriptase-Polymerase Chain Reaction
Drug Metab. Dispos., January 1, 2009; 37(1): 32 - 40.
[Abstract] [Full Text] [PDF]


Home page
Protein Eng Des SelHome page
A.-S. Patana, M. Kurkela, M. Finel, and A. Goldman
Mutation analysis in UGT1A9 suggests a relationship between substrate and catalytic residues in UDP-glucuronosyltransferases
Protein Eng. Des. Sel., September 1, 2008; 21(9): 537 - 543.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
M. H. Court, S. Hazarika, S. Krishnaswamy, M. Finel, and J. A. Williams
Novel Polymorphic Human UDP-glucuronosyltransferase 2A3: Cloning, Functional Characterization of Enzyme Variants, Comparative Tissue Expression, and Gene Induction
Mol. Pharmacol., September 1, 2008; 74(3): 744 - 754.
[Abstract] [Full Text] [PDF]


Home page
Drug Metab. Dispos.Home page
S. Kaivosaari, P. Toivonen, O. Aitio, J. Sipila, M. Koskinen, J. S. Salonen, and M. Finel
Regio- and Stereospecific N-Glucuronidation of Medetomidine: The Differences between UDP Glucuronosyltransferase (UGT) 1A4 and UGT2B10 Account for the Complex Kinetics of Human Liver Microsomes
Drug Metab. Dispos., August 1, 2008; 36(8): 1529 - 1537.
[Abstract] [Full Text] [PDF]


Home page
Drug Metab. Dispos.Home page
G. Chen, R. W. Dellinger, D. Sun, T. E. Spratt, and P. Lazarus
Glucuronidation of Tobacco-Specific Nitrosamines by UGT2B10
Drug Metab. Dispos., May 1, 2008; 36(5): 824 - 830.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2007 by the American Society for Pharmacology and Experimental Therapeutics